Targeting TGF beta 2 mRNA Using Antisense Technology as a New Therapeutic Option in Retinal Diseases

Time: 2:00 pm
day: Day Two


  • Targeting TGF beta 2 mRNA using antisense technology as a new therapeutic option in retinal diseases
  • Our lead compound ISTH0036 is a first in class selective second-generation antisense oligonucleotide (ASO) blocking TGF-β2
  • The phase 1 dose escalation study confirmed the excellent safety profile
  • Currently phase 2 trials are assessing efficacy in wet AMD and DME